1. Inicio
  2. Investigación
  3. Grupos de investigación
  4. Patología Molecular del Cáncer

Patología Molecular del Cáncer

Buscador de publicaciones

Sólo se han incluido artículos originales, editoriales y revisiones.

  • Carmona-Bayonas A, Álvarez Escola C, Ballester Navarro I, Hernando Cubero J, Mangas Cruz MÁ, Garcia-Centeno R, Iglesias C, García-Donas J, Picón MJ, Paja M, González Batanero L, García L, Alonso Gordoa T, López C, Hanzu F, Martínez Trufero J, Febrero Sánchez B, Saiz López P, Blanco Carrera C, Ramón Y Cajal T, Veiguela B, Gressani O, Valdés N, Jimenez-Fonseca P.

    Does Adjuvant Mitotane Impact Cure Rates in Adrenocortical Carcinoma? Insights From the ICARO-GETTHI/SEEN Registry

    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM . 110(11): 3155-3167. Nº de citas: 2

    [doi:10.1210/clinem/dgaf082]

  • Lopez-Janeiro A, Brizzi E, Ruz-Caracuel I, Alexandru R, de Andrea C, Berjón A, Yebenes L, Mendiola M, Heredia-Soto V, Montero-Calle A, Barderas R, de Los Rios V, Redondo A, Pelaez-Garcia A, Hardisson D.

    The Proteomic Landscape of CTNNB1 Mutated Low-Grade Early-Stage Endometrial Carcinomas

    Cells . 14(21): .

    [doi:10.3390/cells14211676]

  • Soria A, Díaz A, Iruzubieta P, Martín-Mateos R, Salcedo-Allende MT, Jiménez-Masip A, Fuster-Anglada C, Arias-Loste MT, Perna C, El Maimouni C, Pericas JM, Ferrer-Gómez A, González CJ, Muñoz-Martínez S, Padilla M, Crespo J, Calixto Z, Sabiote C, Albillos A, Cervera M, Olivas I, Arvaniti P, Hernández-Évole H, Jiménez-Esquivel N, Gratacós-Ginès J, Juanola A, Pose E, Coll M, Nadal R, Pérez-Guasch M, Fabrellas N, Ginès P, Londoño MC, Graupera I.

    Autoantibodies are associated with worse outcomes in MASLD

    JHEP REPORTS . 7(10): 101470-101470.

    [doi:10.1016/j.jhepr.2025.101470]

  • Servitja S, Castro-Henriques M, Álvarez-Busto I, Díez-Franco C, Medina-Castillo A, Algarra-García MA, López-Miranda E, Lario-Martínez M, Luengo-Alcázar MI, Borregón M, Davó A, Gasull-Delgado A, Roque-García S, Gonzaga-López A, Poveda-Ferriols JM, Pascal S, Mitroi-Marinescu AM, García-Escolano M, Fernández-Carvajal A, Ferrándiz-Huertas C, Ferrer-Montiel A.

    A topical nociceutical formulation ameliorates chemotherapy-induced peripheral neuropathy: a pilot randomized clinical study

    CLINICAL & TRANSLATIONAL ONCOLOGY . : .

    [doi:10.1007/s12094-025-04062-1]

  • Martínez-Puente N, Ruz-Caracuel I, Leandro-García LJ, Pian-Arias H, Vega-Corral Z, Letón R, Radu R, Berrizbeitia M, Mellid S, Reglero C, Salazar-Hidalgo ME, Arroba E, Díaz-Talavera A, Marazuela M, Benito-Berlinches A, González-García I, Campos-Mena S, Lozano-Escario MD, Guadalix S, Calatayud M, Pérez-Campos A, Lahera M, Cascón A, Galofré JC, Currás-Freixes M, Caleiras EJ, Valderrabano P, Robledo M, Montero-Conde C.

    Expression of Homo Sapiens (Hsa)-miR-139-5p as a Clinically Feasible Prognostic Marker for Differentiated Thyroid Cancer

    LABORATORY INVESTIGATION . 105(10): 104199-104199.

    [doi:10.1016/j.labinv.2025.104199]

  • Konstantinopoulos PA, Kim JW, Freyer G, Lee JY, Gaba L, Grisham RN, Colombo N, Wu X, Sehouli J, Cruz F, Cibula D, Monk BJ, Nyvang GB, Friedlander M, Lorusso D, Van Nieuwenhuysen E, Malik R, Glasspool R, Marth C, Leary A, Cortés-Salgado A, Zamagni C, Marmé F, Sufliarsky J, Hinson P, Zuradelli M, Wang C, Su F, Paule I, Miller M, Matulonis UA, González-Martín A.

    Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation

    JOURNAL OF CLINICAL ONCOLOGY . 43(26): 2908-2917. Nº de citas: 2

    [doi:10.1200/JCO-25-00225]

  • Eskander RN, Corr B, Cibula D, Tan DSP, Cloven N, Guerra E, Hasegawa K, Myers T, You B, Makker V, Zagouri F, Gien LT, Bartoletti M, Mallen A, Woelber L, Mocci S, Komatsubara K, Ma L, Colombo N.

    A randomized, phase III study of sacituzumab govitecan versus treatment of the physician's choice in patients with endometrial cancer after platinum-based chemotherapy and immunotherapy: the ASCENT-GYN-01 study (GOG-3104/ENGOT-en26/APGOT-EN2).

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society . : 102654-102654.

    [doi:10.1016/j.ijgc.2025.102654]

  • Aguzzi C, De Summa S, Molina-Cerrillo J, Alonso-Gordoa T, Nabissi M, Rizzo M, Zeppellini A, Sunela K, Sorgentoni G, Ortega C, Massari F, Marques Monteiro FS, Battelli N, Porta C, Santoni G, Santoni M.

    mRNA expression, tumor heterogeneity, and response to therapy in patients with advanced renal cell carcinoma treated with immune-based combinations (ARON-1a)

    Biochemistry and Biophysics Reports . 43: 102162-102162.

    [doi:10.1016/j.bbrep.2025.102162]

  • Manso L, Sánchez-Bayona R, Guerra JA, Cortés-Salgado A, Cejalvo JM, Garcia-Saenz JA, Morales S, González-Cortijo L, Mourón S, Bueno MJ, Garma LD, Quintela-Fandino M.

    A Phase IB Study of Binimetinib and Palbociclib in Molecularly Selected Advanced Triple-Negative Breast Cancer

    Cancer Research Communications . 5(9): 1728-1737.

    [doi:10.1158/2767-9764.CRC-25-0428]

  • Massari F, Mollica V, Kopp RM, Grande E, Fiala O, Kanesvaran R, Li H, Schieber TJ, Juan Fita MJ, Poprach A, Lolli C, Bourlon MT, de Liaño AG, Grillone F, Sunela K, Rizzo A, Ghosn M, Cerbone L, Taha T, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, Lenci E, Martin IO, Abu-Sini H, Rescigno P, Bhuva D, Fay AP, Conteduca V, Yildirim A, Rosellini M, Akova U, Tassinari E, Bölek H, Soares A, Marques Monteiro FS, Buti S, Bilen MA, Santoni M.

    Immune-based Combinations in Intermediate-/Poor-risk Patients with Non-clear Cell Renal Cell Carcinoma: Results from the ARON-1 Study

    European Urology Focus . 11(5): 736-746.

    [doi:10.1016/j.euf.2025.05.020]

  • Quindós-Varela M, Soto de Prado-Otero D, Gallego A, García Y, Guerra E, Estévez-García P, Barretina-Ginesta MP, Borraz P, González-Martín A, Rubio MJ.

    Management and Clinical Outcomes of Patients with Advanced Ovarian Cancer in Routine Clinical Practice in Spain: The OVOC Study

    Oncology and therapy . 13(3): 631-648.

    [doi:10.1007/s40487-025-00347-1]

  • López-Miranda E, Pérez-García JM, Gión M, Ribelles N, Cortez-Castedo P, Alonso-Romero JL, García MM, González-Santiago S, Bermejo B, Morales S, Carañana V, Garrigós L, Fernández-Pinto M, García-Vicente S, Garcia-Sanz A, Mena-Molina A, Boix O, Alcalá-López D, Llombart-Cussac A, Cortés J.

    Ipatasertib combined with non-taxane chemotherapy for patients with previously treated advanced triple-negative breast cancer: the PATHFINDER phase IIa trial

    BREAST CANCER RESEARCH . 27(1): 141-141.

    [doi:10.1186/s13058-025-02089-4]

  • Gion M, Blancas I, Cortez-Castedo P, Cortés-Salgado A, Marmé F, Blanch S, Morales S, Díaz N, Calvo-Plaza I, Recalde S, Martínez-Bueno A, Ruiz-Borrego M, Llabrés E, Taberner MT, de Laurentiis M, García-Vicente S, Guerrero JA, Boix O, Rodríguez-Morató J, Sampayo-Cordero M, Antonarelli G, Pérez-García JM, Cortés J, Llombart-Cussac A.

    Atezolizumab plus paclitaxel and bevacizumab as first-line treatment of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial

    NATURE MEDICINE . 31(8): 2746-2754. Nº de citas: 8

    [doi:10.1038/s41591-025-03734-3]

  • Kime A, Bataillon G, Treilleux I, Callens C, Selle F, Heitz F, Cinieri S, González-Martin A, Schauer C, Lindahl G, Parma G, Vergote I, Matsumoto T, Blonz C, Canzler U, Mosconi AM, Guerra Alía EM, Pujade-Lauraine E, Genestie C, Ray-Coquard I, Just PA.

    Can Morphology and Immune Infiltration Predict the Homologous Recombination Deficiency Status in Newly Diagnosed High-Grade Serous Ovarian Carcinoma? Lessons From the PAOLA-1/ENGOT-ov25 Trial, a GINECO Study

    Archives of pathology & laboratory medicine . 149(8): 741-750. Nº de citas: 2

    [doi:10.5858/arpa.2024-0081-OA]

  • Bourlon MT, Galli L, Grande E, Park SH, Melichar B, Schieber TJ, Juan-Fita MJ, Ürün Y, Molina-Cerrillo J, Alonso-Gordoa T, De Giorgi U, Kucharz J, Pérez Calabuig E, Conteduca V, Taha T, Rescigno P, Abu-Sini H, Spinelli GP, Manneh Kopp R, Salfi A, Bhuva D, Valdez-Sandoval P, Mendez-Bribiesca S, Fiala O, Buti S, Marques Monteiro FS, Bamias A, Ghosn M, Massari F, Ansari J, Santoni M.

    Nivolumab plus cabozantinib in metastatic renal cell carcinoma: real-world evidence from the international ARON-1 study

    Frontiers in Oncology . 15: 1605282-1605282. Nº de citas: 1

    [doi:10.3389/fonc.2025.1605282]

  • Zapatero A, Alonso-Gordoa T, Rodríguez Antolín A, Couñago F, Sanmamed N, Domínguez Esteban M, López Valcárcel M, Manneh R, Borque-Fernando Á, Sala González N, Maroto P.

    Triplet systemic therapy for hormone-sensitive prostate cancer: a critical review with a multidisciplinary approach.

    Oncology Reviews . 19: 1599292-1599292.

    [doi:10.3389/or.2025.1599292]

  • Manneh R, Molina-Cerrillo J, de Velasco G, Ibatá L, Martínez S, Ruiz-Granados Á, Alonso-Gordoa T.

    PARP Inhibitors for Metastatic CRPC: More Answers than Questions, a Systematic Review and Meta-Analysis

    PHARMACEUTICALS . 18(7): .

    [doi:10.3390/ph18071015]

  • Téllez L, Toledano M, Álvarez M, Garrido-Lestache E, Garrido E, Guerrero A, Donate J, Canova L, Torres M, Perna C, Del Cerro MJ, Albillos A.

    Distinctive hemodynamic phenotype in Fontan-type circulation patients with distal esophageal varices

    HEPATOLOGY . : . Nº de citas: 2

    [doi:10.1097/HEP.0000000000001472]